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Abstract
Background: Meningiomas are generally slowly growing intracranial tumors. They are often incidentally diagnosed,
given that symptoms may be absent even in cases of an enormous tumor size. Headache is a frequent but not consistent
symptom. Therefore, we examined the association between structural, biochemical and histochemical tumor parameters
with preoperative as well as postoperative occurrence of headache.
Methods: In our study, we prospectively investigated 69 consecutive patients enrolled for meningioma neurosurgery.
Anatomical, histological and biochemical parameters were acquired, and headache parameters were registered from the
clinical report and from a questionnaire filled by the patients before neurosurgery. The headache was re-evaluated one
year after neurosurgery. The study was designed to exploratively investigate whether there is an association of acquired
clinical and biological parameters with the occurrence of preoperative and postoperative headache.
Results: Edema diameter and the proliferation marker MIB-1 were negatively associated with the incidence and intensity
of preoperative headache, while the content of prostaglandin E2 in the tumor tissue was positively associated with
preoperative headache intensity. Headache was more prevalent when the meningioma was located in the area
supplied by the ophthalmic trigeminal branch. Compared to preoperative headache levels, an overall reduction was
observed one year postoperative, and patients with a larger tumor had a higher headache remission. In parietal and
occipital meningiomas and in those with a larger edema, the percentage of the headache remission rate was higher
compared to other locations or smaller edema. Multivariable analyses showed an involvement of substance P and
prostaglandin E2 in preoperative headache.
Conclusions: The study demonstrates new associations between meningiomas and headache. The postoperative head-
ache outcome in the presented patient sample is encouraging for the performed neurosurgical intervention. These
results should be tested in a prospective study that incorporates all patients with meningiomas.
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Introduction
Meningiomas are the most frequent type of all primary
intracranial tumors. In more than 90% of cases they are
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benign (1) and are clinically only recognized when they
are accompanied by neurological deficits or abnormal
functions. Meningiomas generally grow slowly and
remain frequently untreated until serious symptoms
occur. The aim of treatment is the complete surgical
removal of the tumor, which may be difficult or
impossible due to the anatomical location (2).
Headache is the most frequent symptom and occurs
in about two thirds of the patients (3,4). Whether a
meningioma causes a headache may depend on com-
pression of specific structures or an increase in intra-
cranial pressure. Other reasons may be endogenously
formed substances that are assumed to interact with
intracranial nociception. Among such substances,
which may be elevated in patients’ plasma during
headaches or which can induce headaches, are neuro-
peptides, in particular calcitonin gene-related peptide
(CGRP), nitric oxide (NO) and its metabolites, and
prostaglandin E2 (PGE2). In a histochemical investi-
gation of pituitary tumors, substance P or CGRP
immunoreactivity was found in about one quarter of
specimens; however, this was not correlated with the
occurrence of headache (5,6). Also, no correlation was
found between gene expression of the meningioma
subtypes and particular features such as vasodilation,
associated headache or key substances like neuropep-
tides or NO synthases (7). In highly malignant glio-
blastomas, the neuronal NO synthase isoform was
increased but this was not the case in lower-grade
glioblastomas or meningiomas (8). The prostaglandin
PGE2 is a common inflammatory mediator, a metab-
olite of arachidonic acid formed through cyclooxy-
genases 1 and 2. In addition to its vasodilatory
effect, PGE2 sensitizes nociceptors (9) and also has
central nociceptive effects (10). Cyclooxygenase inhibi-
tors are among the most frequently used drugs for
unspecific headaches. The inducible cyclooxygenase 2
was demonstrated immunohistochemically in many
meningiomas and, as for the NO synthase, the
degree of cyclooxygenase 2 expression was associated
with the malignancy of the tumors (11). However,
meningioma-associated headaches did not correlate
with cyclooxygenase 2 expression (7). The growth of
meningiomas seems to be promoted in an autocrine
manner (12), but also by the peptide cholecystokinin.
A possible link between the production of cholecysto-
kinin and headache has not been studied so far. The
first aim of our study was to identify biological men-
ingioma parameters that are associated with preopera-
tive occurrence and intensity of headache. Prior
studies looked at postoperative outcome other than
headache in patients with meningioma, including
investigation of the meningioma location, the meningi-
oma cell type and grading, coexisting symptoms, an
occurrence of particular postoperative symptoms, the
operating techniques, age subpopulations, the recur-
rence rate and the outcome due to additional proced-
ures or diagnostics. (7,13–24). Thus, the second aim of
our study was to identify parameters in an operated
patient sample that are predictive for postoperative
headache, which has not been focused on before.
Materials and methods
Ethical approval and patient recruitment
The study was approved by the ethical review board
of the Medical Faculty of the University of Erlangen-
Nu¨rnberg. In total, all 69 patients diagnosed with
meningioma and operated on at the Department of
Neurosurgery of the University of Erlangen-Nu¨rnberg
in the period 2010–2012 were included in the study,
no patients were excluded. A written informed consent
was provided by all patients or their legal representa-
tives. Patient charts containing clinical data, laboratory
measurements and radiological results of the patients
were acquired for analysis.
Questionnaire and data acquisition
Within the 69 included operated patients, 59
completed a headache-focused questionnaire developed
by Dr. Michael Ku¨ster (KSFB-Bonn, devised by the
Pain Center of the German Pain Society in Bonn,
Germany). The original German questionnaire is avail-
able with permission as a supplement, in addition there
is also an English translation of the questionnaire.
The patients answered the questionnaire at least until
the day before the surgery. In all cases, the question-
naire was completed before an optional medication
with dexamethasone. Some patients had help from
relatives to complete the questionnaire. From this
questionnaire with 39 items, only the following
items were selected to investigate a possible association
with headache and biological parameters of the
meningioma. Patients with more than infrequent head-
ache (once per month, according to ICHD 3-beta)
were classified as headache-positive and asked to rate
the typical intensity of their headache. The headache
intensity was rated on a numerical rating scale ranging
from 0 to 51. The numerical rating scale was addition-
ally graded by a verbal pain rating, the latter not
being considered in our analysis. None of the patients
with meningioma undergoing neurosurgery in the
study period were excluded; three of these patients
were considered to have meningiomatosis. Within
the patient cohort, the prevalence of other diseases
was recorded. Three patients had an intracranial
pathology, that is, one patient had a cerebral infarction,
one had a thalamus infarction, and one had a
534 Cephalalgia 39(4)
prolactinoma. In addition, one patient suffered from
epilepsy, two had a psychoorganic syndrome, one had
leukemia, one had Cushing’s disease, one had multiple
sclerosis, and one had a spinal osteoblastoma. One
patient suffered from migraine, which persisted after
the surgery. In addition, the localization of the head-
ache and the intake of medication for pain relief was
recorded.
In patients with preoperative headache, this was
classified as ‘‘7.4.1 Headache attributed to intracranial
neoplasm’’ according to ICHD 3-beta (25). This is due
to the presence of headache, an intracranial neoplasia,
the temporal relation of headache to the intracranial
neoplasia in most of the patients and headache relapse
in relation to the neurosurgery. For those patients
in which 7.4.1 C2b ‘‘headache has significantly
improved in temporal relation’’ to the operation does
not apply, the best classification might be 7.4.1D, that
is patients ‘‘not better accounted for by another ICHD-
3 diagnosis’’.
The occurrence of postoperative headaches one year
after surgery was assessed during a follow up visit
or via phone contact by the neurosurgeon. The post-
operative evaluation determined headache with the
same criteria and on the same 0–51 pain scale as used
by the preoperative questionnaire. The meningioma
size was determined in preoperative magnetic resonance
imaging. The diameter of the preoperative edema was
determined by the neurosurgeon F.S. using preopera-
tive magnetic resonance imaging.
Biological tumor analysis
Samples of 61 meningiomas were processed for immu-
nohistochemistry and their neuropeptide content.
The resected tissue was placed in isotonic electrolyte
solution and immediately frozen in liquid nitrogen
until further processing. For immunohistochemistry,
one part was fixed in 4% paraformaldehyde with
0.01% picric acid. The fixation period was adjusted
for the size of the tissue, assuming a diffusion of
about 0.5mm/h. The samples were incubated in phos-
phate buffered saline overnight and immersed in 10%
sucrose for 24 hours before freezing. Finally, they were
embedded in TissueTek, frozen in methylbutane and
stored at 20C. The second part of the tumor
sample was stored at 20C without fixation to deter-
mine the total content of substances addressed below
(26). Briefly, the cryoconserved samples were thawed
and washed in synthetic interstitial fluid containing, in
mM: 107.8 NaCl, 26.2 NaCO3, 9.64 Na-gluconate, 7.6
sucrose, 5.55 glucose, 3.48 KCl, 1.67 NaH2PO4, 1.53
CaCl2 and 0.69 MgSO4 (27). After weighting, samples
were immersed in 2 M acetic acid, heated to 95C and
boiled for 10minutes. Afterwards, the tissues were
homogenized with a custom-made homogenizer. The
samples were boiled a second time for 10minutes at
95C in 2M acetic acid and centrifuged for 30minutes
at 10,000 g. The supernatant was removed and 3M
NaOH was added to adjust to a pH of 5.2–7.4. In
these samples, the content of PGE2, substance P and
CGRP was determined by specific enzyme-linked
immune assays as indicated by the manufacturer
(Bertin, France) and as previously described (28).
Whole protein content was determined by a kit
(ThermoFischer, Waltham, MA). The protein concen-
tration and the neuropeptide content of the samples
was detected photometrically by a microplate reader
(Opsys MR-Dynex Technologies, Germany). The
tumor proliferation index MIB-1 of most tumors has
been described (29). This uses a monoclonal antibody
as a cell proliferation marker on routine histologic
material to determine the proliferative activity of
Ki-67 protein (30). The latter is present during all
active phases of the cell cycle and is therefore a useful
tool for detecting the clinical course of the disease.
Statistical procedures
The study was prospective and designed to investigate
potential associations of acquired parameters with
occurrence of preoperative and postoperative headache
in an exploratory manner. Further, associations
between acquired parameters had an exploratory char-
acter and therefore no endpoints were predefined. First,
independent parameters were pairwise tested for correl-
ation. This was calculated with a product-momentum
correlation for two continuous variables and by a
Spearman correlation when at least one non-parametric
variable was included. Due to the exploratory nature
of the present study, in this phase no correction for
multiple testing was employed. Chi-square tests were
used to test 2 2 and 2 3 case contingency tables
with a Yates’s correction where required. Two groups
were compared by t-tests for independent samples.
Bonferroni-Holm correction was used to adjust p-levels
in case of linked tests. Multiple groups were evaluated by
analysis of variance (ANOVA), followed by Tukey’s
HSD post-hoc test for pairwise comparisons.
To specifically address a possible involvement of
the neuropeptides CGRP and substance P and the
lipid mediator PGE2 in preoperative headache, two
hierarchical, multiple regression models were applied:
To predict the occurrence (yes and no) of preoperative
headache in all patients, binary logistic regression was
used. Firth logistic regression was applied due to the
low number of patients without preoperative headache
taking pain medication (31,32). For patients with pre-
operative headache, its intensity (1–51) was modeled
using multiple linear regression. In both logistic and
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linear regression, the following combination of pre-
dictors was used: Model 1 contained pain medication
(yes and no) and maximal tumor diameter; in Model 2,
concentrations of CGRP, Substance P and PGE2, all
log-transformed to base 2, were entered in addition.
The likelihood ratio Chi-square statistic was used to
test i) if Model 1 predicts headache occurrence and
intensity; ii) if Model 2 predicts headache occurrence
and intensity; iii) if Model 2 predicts headache occur-
rence and intensity better than Model 1; iv) to what
extent the individual variables contribute to the
models; and v) if the individual variables predict head-
ache occurrence and its intensity.
All statistical tests were two-sided, p< 0.05 was con-
sidered statistically significant. Data are presented as
meanSEM, in case of skewed distributions with a
Shapiro-Wilk test for normality of p< 0.05, median
and interquartile range is given. Analyses were per-
formed using Statistica (StatSoft, Tulsa, USA) and
IBM SPSS Statistics 24.
Results
Meningiomas of 69 patients (47 female) were removed
by neurosurgery (Table 1). There was no significant
age difference between the sexes (p¼ 0.65, U-test),
the median age of all patients was 58 (range 34–82)
years. However, the meningioma grade was higher
and the maximum diameter and surrounding edema
was larger in males compared to females (p¼ 0.046,
Chi-square, 0.035 and 0.040, U-tests, Figure S1).
Preoperative questionnaires and clinical data were
investigated, primarily for their association with pre-
and post-operative headache. The largest diameter,
which was used for classification of the meningiomas,
was 39 2mm on average; in 17 tumors it was below
3 cm, in 42 within the range of [3–6] cm, and in 10
above 6 cm. More than half (36/69) of the meningiomas
were localized in the frontal lobe, five temporal, 16 par-
ietal and 12 occipital. The edema around the meningi-
oma on preoperative MR images had a median
diameter of 10mm (interquartile range 0–35mm). The
edema diameter was correlated with the measures of
tumor size, including largest diameter and tumor
volume (R¼ 0.51, 0.40 and all p< 0.001, product-
momentum correlation, Figure S2(a)–(c)). The edema
was smaller for meningiomas in the occipital lobe and
for meningiomas in areas innervated by C1–C3 com-
pared to other meningiomas (p¼ 0.003 and 0.047, U-
test, Figure S2(d)). The median substance P levels of the
meningioma tissue were 29 pg/ml (interquartile range
19–55), and higher values were observed in tumors
with larger volume (R¼ 0.31, p¼ 0.035, product-
momentum correlation, Figure S3(a)). Compared to
the other lobes, frontal meningiomas had higher sub-
stance P levels (p¼ 0.047, bootstrapped t-test, Figure
S3(b)). Median CGRP levels of the meningioma tissue
were 6 pg/ml (interquartile range 2–10) and were not
associated with tumor parameters or headache occur-
rence. Dexamethasone was given in 30 of 69 patients,
based on the edema in the magnetic resonance imaging.
Dexamethasone application to reduce volume for the
operation was more frequent in tumors with higher
WHO grading and larger maximum diameter
(p¼ 0.002 and p¼ 0.002, U-tests). Based on these
results, unsurprisingly patients receiving glucocortic-
oids were predominantly male (p¼ 0.021, Chi-square).
Preoperative headache: Univariate analyses
Preoperative headache exceeding an infrequent rate
(once per month, according to ICHD 3-beta) was
reported by 60% (38/63) of patients. The headaches
did not conform to characteristic primary headaches
such as migraine or cluster headache, no characteristic
pattern of the headache was recorded, as it was
reported in previous studies (33). The preoperative
Table 1. Patient characteristics and sample size in absolute
numbers and percentage.
Count %
Patients included (Meningioma diagnosis
and respective neurosurgery)
69 100
Female 47 68
Male 22 32
Preoperative magnetic resonance imagi-
ng (includes meningioma measurement
and location)
69 100
Preoperative headache assessed (ques-
tionnaire completed)
62 90
Without preoperative headache 24 35
With preoperative headache 38 55
Postoperative headache assessed 65 94
Without postsurgical headache 53 77
With postsurgical headache 12 17
Pre- and postoperative headache assessed 60 87
Without preoperative headache 23 33
With preoperative headache 37 54
With preoperative, without postsurgical
headache
28 41
With preoperative, with postsurgical
headache
9 13
Biological parameters
Grading (histopathology) 68 99
MIB-1 (histopathology) 24 35
Neuropeptide measurement 59 86
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incidence of headache was 71% (27/38) in patients with
meningiomas innervated by the first trigeminal branch,
which is higher than 44% (11/25) for the second and
third trigeminal branch (p¼ 0.032, Chi-square test,
Figure 1). Compared to the functional classification,
in a simpler anatomical classification to frontal, tem-
poral, parietal and occipital, no significant differences
were observed. The preoperative incidence or intensity
of the headache was not associated with the maximum
tumor diameter (Rs¼ 0.004 and 0.076, p¼ 0.98 and
0.57, Spearman correlations). The location of the sen-
sation of headaches was not associated with the loca-
tion of meningiomas. This is in agreement with a
previous intraoperative study, where stimulation of
different sites of the exposed dura mater caused wide-
spread referral of pain, which did not coincide with the
expected trigeminal areas (34). For the 12 patients, who
had both a unilateral headache and a unilateral men-
ingioma, there was no positive or negative association
between the side of the headache and the side of the
meningioma (p¼ 0.61, Chi-square test). Patients with
an edema above 10mm had a preoperative headache
rating of 9 3, which is lower than the 19 3 reported
by patients with smaller edema (p¼ 0.044, n¼ 24 and
28, U-test, Figure 1(b)). The edema around the tumors
was negatively associated with the preoperative head-
ache intensity (R¼0.28, p¼ 0.048, product-momen-
tum correlation, Figure 1(c)). The tumor proliferation
index MIB-1 was higher in patients without than in
patients with preoperative headache (p¼ 0.020, U-test,
determined in 24 patients, Figure 2(a)). The MIB-1 was
negatively associated with the intensity of preoperative
headache (R¼0.51, p¼ 0.015, product-momentum
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Figure 1. (a) Preoperative headache is associated with innerv-
ation. Meningiomas were classified according to the innervation
territory of the three trigeminal branches and spinal nerves C1–
C3. Meningiomas in the territory of the ophthalmic branch were
more frequently associated with headache compared to the
other cases. (b) Preoperative edema diameter, here thresholded
at 10mm, is negatively correlated with the preoperative head-
ache rating. (c) Scatterplot of the edema around the tumors and
the preoperative headache intensity.
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Figure 2. Biological parameters associated with preoperative
headache. (a) Patients without preoperative headache had a
higher tumor proliferation index MIB-1 compared to patients
without preoperative headache. (b) The MIB-1 was negatively
correlated with the intensity of preoperative headache. (c)
Prostaglandin E2 concentration in meningiomas of patients with
and without preoperative headache. (d) The levels of prosta-
glandin E2 in the meningioma were correlated with the intensity
of preoperative headache.
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correlation, Figure 2(b)). Median PGE2 levels in men-
ingioma tissue were 354pg/ml (interquartile range 158–
581) and were positively correlated with the intensity of
preoperative headache (R¼ 0.34, p¼ 0.019, n¼ 48, pro-
duct-momentum correlation, Figure 2(c),(d)). Substance
P levels failed to reach significance (R¼ 0.37, p¼ 0.071,
n¼ 44, product-momentum correlation).
Preoperative headache: Multivariable analyses
Multivariable analyses were used to assess to what
degree CGRP, Substance P and PGE2 predict occur-
rence and intensity of preoperative headache while con-
trolling for some known confounders. For occurrence
of preoperative headache, Firth logistic regression was
used for its intensity linear regression. Results are listed
in Table 2. A total of 36 patients took no medication.
The sample size was insufficient to allow a sub-analysis
for individual substances or substance classes with ade-
quate statistical power (10 patients took acetyl salicylic
acid, 10 ibuprofen, four metamizol, three acetyl sali-
cylic acid þ paracetamol þ caffeine, two diclophenac,
one amitryptilin, one etoricoxib, one paracetamol, one
tilidine, one tramadol and two patients a triptan).
In Firth logistic regression, Model 1 including the
variables pain medication and maximal tumor diameter
predicted the occurrence of headache significantly
better than a basic model without predictors (Model
1: 2 (2)¼ 13.0, p¼ 0.002), whereby only the variable
pain medication contributed significantly (2 (1)¼ 12.8,
p< 0.001). To test the predictive value of CGRP, sub-
stance P and PGE2, their concentration was added in
addition (Model 2). Although Model 2 also signifi-
cantly predicted headache occurrence in general
(Model 2: 2 (5)¼ 12.4, p¼ 0.029), it was not better
than Model 1 (Model 2 vs. Model 1, p¼ 0.91).
In multiple linear regression, Model 1 did not sig-
nificantly predict headache intensity (R2¼ 0.19,
2 (2)¼ 4.28, p¼ 0.09). Addition of CGRP, substance
P and PGE2 concentration significantly improved the
model, increasing the coefficient of determination by
0.36 to 0.55, which was statistically significant (Model
2 vs. Model 1: 2 (3)¼ 11.2, p¼ 0.010). While the effect
of CGRP was not significant, substance P and PGE2
significantly predicted headache intensity (p¼ 0.006
and 0.014). The partial correlation coefficients for sub-
stance P and PGE2 concentration with preoperative
headache were 0.512 and 0.509, respectively.
Calculation of overall likelihood ratio statistics
with respective p-values showed that pain medication,
maximal tumor diameter, substance P and PGE2 con-
centration significantly predicted preoperative head-
ache, whereas no such effect was observed for CGRP
concentration.
Post-operative headache
The percentage of all patients without postoperative
headache increased with the T-staging (Rs¼ 0.25,
p¼ 0.043, Spearman correlation, Figure 3(a)). Also,
within patients with preoperative headache, the percent-
age of patients who became headache-free after the sur-
gery increased with the T-staging (Rs¼ 0.34, p¼ 0.042,
Spearman correlation, Figure S4). These results are
similar when an at least 50% reduction in the
postoperative headache rating is considered instead of
complete absence of headache. Further of interest is
the predictive value of the anatomical location.
Table 2. Hierarchical multivariable regression models testing the effects of CGRP, substance P and PGE2 concentrations within
meningiomas on preoperative headache occurrence and intensity.
Firth logistic regression Linear regression Overall
95% CI for Odds Ratio 95% CI for b
Lower
Odds
Ratio Upper 2 (df) p Lower b Upper 2 (df) p 2 (df) p
Model 1 13.0 (2) 0.002 4.72 (2) 0.09
Pain medication (yes/no) 3.33 17.9 186 12.8 (1) <0.001 2.51 8.41 19.3 2.36 (1) 0.13 15.2 (2) <0.001
Maximal tumor diameter (cm) 0.60 1.08 1.95 0.06 (1) 0.80 5.81 2.58 0.66 2.51 (1) 0.11 2.57 (2) 0.28
Model 2 12.4 (5) 0.029 15.9 (5) 0.007
Pain medication (yes/no) 2.56 12.7 122 10.5 (1) 0.001 1.18 9.72 18.3 4.86 (1) 0.028 15.4 (2) <0.001
Maximal tumor diameter (cm) 0.63 1.12 2.08 0.15 (1) 0.70 6.93 4.00 1.08 6.73 (1) 0.009 6.88 (2) 0.032
CGRP (log2 pg/ml) 0.41 0.80 1.50 0.47 (1) 0.49 1.61 1.28 4.17 0.81 (1) 0.37 1.28 (2) 0.52
Substance P (log2 pg/ml) 0.57 1.08 2.21 0.06 (1) 0.81 1.43 4.42 7.41 7.65 (1) 0.006 7.70 (2) 0.021
Prostaglandin E2 (log2 pg/ml) 0.69 1.14 1.77 0.39 (1) 0.53 0.55 2.49 4.42 6.04 (1) 0.014 6.43 (2) 0.040
Comparison of Model 1 and 2 0.53 (3) 0.91 11.2 (3) 0.010
Note. Bold numbers denote significant associations with preoperative headache.
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In patients with frontal and temporal meningioma, the
postoperative incidence of headache was about half of
the preoperative incidence; for the parietal and occipital
cases, all patients were headache-free after the operation
(Figure 3(b)). Anatomical locations of particular interest
did not comprise enough patients to allow meaningful
statistical analysis. In 57 of 69 patients, the meningioma
could be fully removed. Complete vs. incomplete
removal was not predictive for occurrence of
postoperative headache (p¼ 0.86, Chi-square test).
Patients with a preoperative edema above 10mm
reported a postoperative headache in 8% (2/26), which
is lower than the 31% (10/32) of patients reporting head-
ache with smaller preoperative edema (p¼ 0.028, Chi-
square test, Figure 3(c)).
According to the study protocol, the three patients
with intracranial pathology were not excluded. The
supplementary statistics tables provide all results pre-
sented above also as sub-analysis for the 66 patients
without intracranial pathology, which did not show
substantial differences.
Discussion
We investigated patients’ headache together with struc-
tural, biochemical and histochemical tumor parameters
before and after meningioma surgery. Edema diameter
and malignancy index MIB-1 were negatively corre-
lated with preoperative headache occurrence, and a
large tumor size was the most important parameter
for a high chance of a postoperative headache reduc-
tion. In our patient sample, a high level of tumor pro-
gression favors intervention and in these patients the
biggest improvements in tumor-associated headache
are predicted.
It should be noted that the study investigated a pre-
operative patient cohort seen and selected for neurosur-
gery at the Department of Neurosurgery of the
University of Erlangen-Nu¨rnberg. This might implicate
a selection bias compared to a cohort of patients with
meningioma at the stage of first diagnosis. For example,
the percentage of patients with symptoms due to the
meningioma is likely to be enriched in a preoperative
cohort referred to neurosurgery when compared to all
subjects with a meningioma, of which many are asymp-
tomatic or not diagnosed. On the other hand, only one
migraine patient was in our sample, substantially below
an expected 6.2 of 69 patients with migraine, calculated
on the basis of age-matched prevalence (35). We cannot
exclude undiagnosed primary headaches in the present
study. However, most primary headaches occur earlier
in life and are therefore typically known already at the
time of meningioma incidence. In primary headache
patients, referral to structural diagnostics might have a
higher threshold. Further, even for those who received
structural diagnostics, there might be a bias against
referral to neurosurgery. Together both reasons might
explain why primary headaches did occur less frequently
in our patients than expected from an unbiased sample.
There was a substantial positive correlation between
the tumor size and the edema diameter, which is not
surprising. However, tumor size but not edema diam-
eter was a good predictor for postoperative outcome.
Although there are many studies about brain tumor
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Figure 3. Postoperative headache. (a) Patients with high tumor
progression had a large reduction in headache due to neurosur-
gical intervention. (b) A complete postoperative absence of
headache was observed for parietal and occipital localized men-
ingiomas, compared to a reduction in frontal and temporal cases.
(c) Percentage of patients with and without postoperative
headache separated by preoperative edema. (d) Within the
subgroup of patients with preoperative headache, the percentage
of patients with and without postoperative headache separated
by preoperative edema. The percentage of patients is given
within the bars of the stacked histograms.
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headache and possible involvement of diverse sub-
stances which might be released, there are still open
questions that have to be answered. There is seminal
work regarding the pain-sensitive structures in the men-
inges, which are perceived as localized headache accord-
ing to the site of stimulation (36,37). They showed that
the dura mater is sensitive to stimulation, and pain is in
particular observed when stimulation was performed
close to arterial vessels, where the branches of the tri-
geminal nerve travel alongside.
Pre-existing primary headache is a risk factor for
developing headache from a brain tumor, which sug-
gests a predisposition for secondary headache (4). In
more than 80% of the patients, the headache changed
with the occurrence of the tumor. Stimulation of the
trigeminal ganglion led to an increase in regional cere-
bral blood flow in the frontal and parietal cortex of cats
(38). The particular importance of the neuropeptide
CGRP in meningeal nociception was the topic of sev-
eral investigations (39–41). Headaches associated with
brain tumors were commonly assumed to be the result
of intracranial pressure and mechanical traction on
pain-sensitive structures. In addition to the mechanical
activation suggested by the results of Ray and Wolff
(37), there are likely also chemical pronociceptive
effects of tumors affecting the nociceptive afferents.
For patients with brain tumors of all etiologies, the
incidence of headache was about 50% (42).
For our analysis, meningiomas were subdivided into
different innervation territories of the three trigeminal
branches and the cervical spinal nerves C1-C3.
Meningiomas in the area of the ophthalmic branch
were more frequently associated with preoperative
headache compared to locations associated with other
branches of the trigeminal nerve. The innervation of the
ophthalmic branch includes the supraorbital region.
It was described that periorbital allodynia occurs due
to an injury in the somatosensory cortex (43). There is
convergent evidence that chemical sensitization or acti-
vation of nociceptive afferents innervating the dura
mater can cause facial allodynia (44,45). The most
likely explanation is convergent input to central nocicep-
tive structures, because the ophthalmic branch of the
trigeminal nerve innervates most of the facial areas
and the dura mater (46). Furthermore, the involvement
of the cavernous sinus has been considered as a source of
headache, since several structures involved in headache
generation such as the internal carotid artery and the
ophthalmic branch of the trigeminal nerve pass here,
but this remained rather speculative (47). Dural stretch
was a traditional explanation for the occurrence of head-
ache, which has not been substantiated.
Our findings show a negative correlation between
preoperative edema diameter and preoperative head-
ache rating of the patients. This appears
counterintuitive at first glance, as a larger edema diam-
eter might cause more intracranial pressure and head-
ache. It should be considered that pressure at nerves
could cause a conduction block and thereby suppress
or silence neurons. An important aspect is the tumor
growth rate. Fast growing tumors are more rapidly
detected than slowly growing ones. The faster growing
tumors, also associated with more edema, might dis-
locate other structures more effectively compared to
the slower growing tumors, which may invade structures
without displacing them. Furthermore, the tumor sub-
type might be important, and there might be pronoci-
ceptive paraneoplastic effects of particular tumor types.
Patients without preoperative headache had a higher
tumor proliferation index (MIB-1). As mentioned
above, faster growing tumors seem to be detected by
other symptoms than pain. The concentration of PGE2
in the meningioma was weakly positively associated
with preoperative headache. PGE2 is a well-known
sensitizer of nociceptive molecular targets such as
TRPV1 (49), which could further promote pronocicep-
tive cascades, including neurogenic inflammation and
activation of non-neuronal structures. Inflammatory
reactions caused by the tumor or brain injuries can
induce plasma extravasation and extracellular accumu-
lation of fluid and proteins. A dysfunction of tight-
junction proteins may also play a role in the occurrence
of edema. Inflammation can also be associated with an
increased permeability of the blood brain barrier, which
might increase edema, and which might expose nerve
fibers to additional excitatory substances.
Fortunately, a large fraction of patients is headache-
free after resection. This occurs more frequently in
patients with larger tumors compared to smaller
tumors. The relief of headache in particular in patients
with larger tumors could be explained by the mechan-
ical effects of the larger volume removed, but other
parameters associated with size such as growth rate
and malignancy should also be considered. Associated
with the latter factors are also biochemical changes,
particularly paracrine (paraneoplastic) effects of the
tumor on its surroundings, which could contribute to
secondary headache.
Considering the tumor location, patients with
preoperative headache and tumors with parietal or
occipital location were completely headache-free after
surgery. An explanation might be the available space,
which might be more tightly limited in areas where
expansion might affect the brainstem. Still, more than
half of the patients with temporal and frontal tumors
became headache-free after surgery. By trend, patients
with a large preoperative edema had more relief of head-
ache after resection of their tumor, which again could be
explained by the mechanical alteration as well as bio-
chemical changes associated with the edema. In males,
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the WHO grade was higher, and tumor diameter and
edema larger compared to females. This could be
explained by more aggressive tumors in males, but
more likely by a well-described higher level of indolence
in males, seeking medical attention in a later stage. A
final point to be considered is whether neurons grow
into tumors due to chemo-attractive stimuli or are chan-
ged in their peripheral expression. Larger tumors had a
higher substance P concentration. Substance P levels
were most substantial in tumors located in the frontal
lobes, but this might at least partially be explained by
the meningeal innervation pattern.
To specifically address a possible involvement of
CGRP, substance P and PGE2 in preoperative head-
ache with adjustment for confounders, we used multi-
variable regression models. The intake of pain
medication and tumor size were regarded as potential
confounders; thus, they were added in a first regression
model (Model 1). Adding CGRP, substance P and
PGE2 in addition (Model 2) allowed testing for if and
which of these variables have additional predictive
value. First, Firth logistic regression was used to
model the occurrence (rating 0 vs.> 0) of preoperative
headache. The fact that pain medication significantly
predicted the presence of preoperative headache is not
surprising. The addition of CGRP, substance P and
PGE2 concentration did not improve the predictive
value of the model, indicating that there is no evidence
that these molecules are involved in the occurrence of
preoperative headache. Importantly, due to the limited
statistical power of this exploratory trial, this cannot be
interpreted as no involvement, it merely indicates the
absence of evidence for an involvement.
Regarding pain intensity (rating 1–51) in patients with
preoperative headache, however, multiple linear regres-
sion supports an involvement of substance P and PGE2.
Together with CGRP concentration, the concentration
of these two molecules within meningiomas explained
considerably more variance of preoperative headache
intensity than pain medication and tumor size alone.
The results suggest that doubling of substance P and
PGE2 concentration increase headache intensity by 4.4
and 2.5 units. The non-significant effect of CGRP con-
centration means that there could be an association with
preoperative headache, but our data provide no evidence
for it. Significant overall likelihood ratio chi-square stat-
istics suggest that pain medication, maximal tumor
diameter, substance P and PGE2 predict preoperative
headache generally.
Limitations of the study: The chosen questionnaire
has some disadvantages. This includes the pain rating
scale, which uses a verbal grouping that might affect the
linearity of the scale, a non-standard number range,
and an untypical upper end of the scale. Further, the
questionnaire was not specifically designed for the pre-
sent study, and therefore an unnecessary effort was
required to answer questions that were not of interest
for this study. Patients were included in the neurosur-
gery department, therefore at a stage when a surgical
option was at least seriously considered. This limits
generalization to other patient cohorts, for example at
an earlier stage in the clinical decision tree. Based on
the late inclusion, the study lacks presurgical data such
as headache frequency and intensity based on a head-
ache diary. It should be considered that dexamethasone
application before surgery might have had an influence
on the levels of the biomarkers. Postoperative head-
aches were investigated once, one year after surgery;
no time course of headache incidence was acquired.
The limited sample size did not allow for statistically
significant numbers in a finer categorization and might
have overlooked existing associations due to the gener-
alization required to get sufficient numbers per group.
A placebo rate due to surgical procedures should be
considered when evaluating the results (50), especially
taking into account that more invasive procedures have
higher placebo rates.
With special focus on associated headache, several
new associations between clinical and experimental
measures have been found in operated patients with
meningioma. However, it has to be noted that due to
the exploratory character of this study, these results
need to be interpreted with caution and considered
to be new hypotheses. Furthermore, due to the obser-
vational study design, no causal relationships can be
established. In this regard, a causal involvement of sub-
stance P might be probed in a clinical study testing the
efficacy of the approved NK1-receptor antagonist apre-
pitant as a symptomatic therapy against tumor-induced
headache.
Key findings
. Preoperative headache intensity was associated with the innervating trigeminal branch, the surrounding
edema, tumor proliferation index MIB-1 and with prostaglandin E2 content. After adjusting for pain medi-
cation intake and maximal tumor diameter, an increase of substance P and of PGE2 concentration within
tumors was associated with higher preoperative pain intensity.
. A high maximal tumor diameter was a predictor for a low probability of postoperative headache
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